تحميل...

Adjuvant therapeutic vaccination in patients with non-small cell lung cancer made lymphopenic and reconstituted with autologous PBMC: first clinical experience and evidence of an immune response

BACKGROUND: Given the considerable toxicity and modest benefit of adjuvant chemotherapy for non-small cell lung cancer (NSCLC), there is clearly a need for new treatment modalities in the adjuvant setting. Active specific immunotherapy may represent such an option. However, clinical responses have b...

وصف كامل

محفوظ في:

التفاصيل البيبلوغرافية
المؤلفون الرئيسيون:	Rüttinger, Dominik, van den Engel, Natasja K, Winter, Hauke, Schlemmer, Marcus, Pohla, Heike, Grützner, Stefanie, Wagner, Beate, Schendel, Dolores J, Fox, Bernard A, Jauch, K-W, Hatz, Rudolf A
التنسيق:	Artigo
اللغة:	Inglês
منشور في:	BioMed Central 2007
الموضوعات:	Research
الوصول للمادة أونلاين:	https://ncbi.nlm.nih.gov/pmc/articles/PMC2020458/ https://ncbi.nlm.nih.gov/pubmed/17868452 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1479-5876-5-43
الوسوم:	إضافة وسم لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

Adjuvant therapeutic vaccination in patients with non-small cell lung cancer made lymphopenic and reconstituted with autologous PBMC: first clinical experience and evidence of an immune response

مواد مشابهة